Clinical trials: Rosuvastatin
Healthy Participants
Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.
- Trial name
- NCT05045638
- Testing
- Rosuvastatin, Sotorasib
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Amgen
Hyperlipidemia
Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia
Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia 8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design
- Trial name
- NCT02280590
- Testing
- Rosuvastatin(Cresnon®), Rosuvastatin(Crestor®)
- Where
- South Korea
- Volunteers
- 223 people
- Sponsor
- Dong-A ST Co., Ltd.
Healthy
Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components
Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe 10 mg. An open design, randomized, single dose with three periods, six sequences and crossed, in healthy volunteers with fasting…
- Trial name
- NCT04895059
- Testing
- Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose, Rosuvastatin 20mg, Ezetimibe 10mg
- Where
- Mexico
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Healthy
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
- Trial name
- NCT00808678
- Testing
- ABT-143, ABT-335, rosuvastatin
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Ischemia Reperfusion Injury, Endothelial Dysfunction
Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury
Rationale: Apart from their cholesterol lowering effects, statins have cholesterol-independent pleiotropic actions, such as upregulation of 5'-ectonucleotidase and up-regulation of NO-synthase that may increase tolerance against…
- Trial name
- NCT00987974
- Testing
- rosuvastatin, atorvastatin 3 days, rosuvastatin 7 days
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy Participants
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative…
- Trial name
- NCT07316608
- Testing
- Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolaemia
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.
- Trial name
- NCT00427960
- Testing
- Dietary advice, rosuvastatin, atorvastatin
- Where
- 9 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Healthy Participants
Potential Drug Interaction Between ALXN2040 and Rosuvastatin
This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.
- Trial name
- NCT05708573
- Testing
- Rosuvastatin, ALXN2040
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Non-ST-elevation Acute Coronary Syndromes
Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)
This is a 30-day, randomized, open-label, 3-arm, parallel-group, multicenter study exploring efficacy of intensive rosuvastatin treatment peri-PCI in Chinese patients with NSTE-ACS.
- Trial name
- NCT02284503
- Testing
- Rosuvastatin
- Where
- China
- Volunteers
- 1,350 people
- Sponsor
- Shanghai Zhongshan Hospital
Leukemia, Myeloid, Acute
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the…
- Trial name
- NCT03720366
- Testing
- enasidenib, Arm 1 probes, Arm 2 Probes
- Where
- 10 sites in Australia, South Korea
- Volunteers
- 40 people
- Sponsor
- Celgene
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.
- Trial name
- NCT05828303
- Testing
- TPX-0005, Metformin Hydrochloride, Digoxin
- Where
- 33 sites in United States, Australia and 4 more
- Sponsor
- Turning Point Therapeutics, Inc.
Rosuvastatin, Heart Failure
Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study
At one site, patients participating in the Corona main study are asked to participate in the PET-substudy. Before and 6 months after study medication is started a Positron Emission Tomography (PET-scan) is performed to study the…
- Conditions
- Rosuvastatin, Heart Failure, Positron Emission Tomography (PET)
- Trial name
- NCT00228514
- Testing
- Rosuvastatin, Positron emission tomography
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.
Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study
Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions.
- Trial name
- NCT01971606
- Testing
- Rosuvastatin
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Yonsei University
Hyperlipoproteinemia Type III
Type III Dysbetalipoproteinemia
Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.
- Trial name
- NCT00214604
- Testing
- Rosuvastatin, pravastatin
- Where
- 2 sites in Norway, South Africa
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Overweight
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
This trial is conducted in china. The aim of the trial is as follows: To assess the effect of multiple subcutaneous injections of JY09 injection on the pharmacokinetic (PK) profile of multiple oral doses of metformin…
- Trial name
- NCT06247748
- Testing
- Exendin-4 Fc fusion protein (JY09) injection, Metformin Hydrochloride tablet, Rosuvastatin calcium tablets
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Hypertension With Dyslipidemia
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
- Trial name
- NCT03247140
- Testing
- JLP-1401, Telmisartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Coronary Heart Disease
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of…
- Trial name
- NCT00235950
- Testing
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel
- Where
- 18 sites in Sweden
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.
- Trial name
- Rosuzet-IVUS (NCT03169985)
- Testing
- Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day, Rosuvastatin 20 mg orally once a day
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Samsung Medical Center
Obesity &Amp; Overweight
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the…
- Trial name
- NCT07065058
- Testing
- Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd